• Journal of the Institute of Electronics Engineers of Korea CI
• /
• v.48 no.4
• /
• pp.21-26
• /
• 2011

Feature ranking is useful to gain knowledge of data and identify relevant features. In this study, we proposed a use of feature ranking for classification of neuro-degeneration and vascular dementia in micro-Raman spectra of platelet. The entire region of the spectrum is divided into local region including several peaks, followed by Gaussian curve fitting method in the region to be modeled. Local minima select from the subregion and then remove the background based on the position by using interpolation method. After preprocessing steps, significant features were selected by feature ranking method to improve the classification accuracy and the computational complexity of classification system. PCA (principal component analysis) transform the selected features and the overall features that is used classification with the number of principal components. These were classified as MAP (maximum a posteriori) and it compared with classification result using overall features. In all experiments, the computational complexity of the classification system was remarkably reduced and the classification accuracy was partially increased. Particularly, the proposed method increased the classification accuracy in the experiment classifying the Parkinson's disease and normal with the average 1.7 %. From the result, it confirmed that proposed method could be efficiently used in the classification system of the neuro-degenerative disease and vascular dementia of platelet.

• Annals of Clinical Neurophysiology
• /
• v.19 no.2
• /
• pp.101-112
• /
• 2017

Detection of underling proteinopathies is becoming increasingly important across neurodegenerative conditions due to upcoming disease intervention trials. In this review, we explored how temporal lobe changes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) can potentially predict underlying TDP-43 pathology subtypes in FTD. To date, emphasis has been given to frontal lobe changes in the study of the cognitive and behavioural impairments in both syndromes but an increasing number of pathological, imaging and neuropsychological studies suggest how temporal lobe changes could critically affect the cognition and behaviour of these conditions. In this current article, we reviewed pathological, imaging as well as clinical/neuropsychological findings of temporal involvement in the ALS-FTD continuum, how they relate to temporal lobe changes and the underlying TDP-43 pathology in FTD. Findings across studies show that TDP-43 pathology occurs and coincides in many structures in ALS and FTD, but especially in the temporal lobes. In particular, anterior and medial temporal lobes atrophy is consistently found in ALS and FTD. In addition, memory and language impairment as well as emotional and Theory of Mind processing deficits that are characteristics of the two diseases are highly correlated to temporal lobe dysfunction. We conclude by showing that temporal lobe changes due to TDP-43 type B might be particular predictive of TDP-43 type B pathology in behavioural variant FTD, which clearly needs to be investigated further in the future.

• Journal of Biomedical Engineering Research
• /
• v.31 no.1
• /
• pp.27-32
• /
• 2010

Noninvasive detection of patients with probable Alzheimer's disease (AD) is of great importance for assisting a medical doctor's decision for early treatment of AD patients. In the present study, we have extracted quantitative electroencephalogram (qEEG) variables, which can be potentially used to diagnose AD, from resting eyes-closed continuous EEGs of 22 AD patients and 27 age-matched normal control (NC) subjects. We have extracted qEEG variables from mean phase coherence (MPC) and EEG coherence, evaluated for all possible combinations of electrode pairs. Preliminary trials to discriminate the two groups with the extracted qEEG variables demonstrated that the use of MPC as a supplementary or alternative measure for the EEG coherence may enhance the accuracy of noninvasive diagnosis of AD.

• Sleep Medicine and Psychophysiology
• /
• v.9 no.1
• /
• pp.9-13
• /
• 2002

Alzheimer's disease (AD) is one of the most common and devastating dementing disorders of old age. Most AD patients showed significant alternation of sleep structure as well as cognitive deficit. Typical findings of sleep architecture in AD patients include lower sleep efficiency, higher stage 1 percentage, and greater frequency of arousals. The slowing of EEG activity is also noted. Abnormalities in REM sleep are of particular interest in AD because the cholinergic system is related to both REM sleep and AD. Several parameters representing REM sleep structure such as REM latency, the amount of REM sleep, and REM density are change in patients with AD. Especially, measurements of EEG slowing during tonic REM sleep can be used as an EEG marker for early detection of possible AD. In addition, a structural defect in the suprachiasmatic nucleus is suggested to cause various chronobiological alternations in AD. Most of alternations related to sleep make sleep disturbances common and disruptive symptoms of AD. In this article, the author reviewed the alternation of sleep structure and circadian rhythm in AD patients.

• Proceedings of the Korea Information Processing Society Conference
• /
• 2009.04a
• /
• pp.1336-1339
• /
• 2009

산업화가 진행된 세계 주요 선진국들은 의학의 발달과 평균 수명의 증가로 고령화의 위기를 겪고 있다. 인구 고령화에 따라 치매 인구도 크게 증가하였다. 치매 인구의 증가는 국가와 가정의 물질적, 인적 비용을 증가시키고 있다. 이와 같은 사회문제를 해결하고 효율적인 치매 환자 관리를 위한 방법이 필요하다. 관찰 대상자가 치매 증상과 비슷하게 행동한다면 치매를 의심해 볼 수 있다. 본 논문에서는 3축 가속도 센서를 사용하여 대상자의 행위 정보를 수집하고 디지털화한다. 디지털화 된 행위정보를 치매 증상의 행동 패턴과 비교하여 관찰 대상자의 행동이 치매 증상인지 정상적인 활동인지 판단할 수 있는 방법을 소개한다.

• Proceedings of the Korea Information Processing Society Conference
• /
• 2023.11a
• /
• pp.1055-1056
• /
• 2023

이 논문은 음성 데이터를 이용하여 치매 징후를 진단하는 프로그램을 개발하는 과정과 결과에 대해 소개한다. MFCC (Mel-frequency cepstral coefficients) 기술을 사용하여 음성 패턴을 추출하고 기계 학습 모델을 적용하여 치매 징후를 탐지하는 방법을 설명한다. 실험 결과는 치매 조기 진단 및 관리에 유용한 음성 기반 도구의 중요성을 강조한다.

• The Journal of Korean Institute of Communications and Information Sciences
• /
• v.38C no.12
• /
• pp.1106-1113
• /
• 2013

For patients who have senile mental disorder such as dementia, quantity of excercise and amount of sunlight are important clue for dose and the treatment. Therefore, monitoring health information of daily life is necessary for patients' safety and healthy life. Portable & wearable sensor device and server configuration monitoring data are needed to provide these services for patients. Watch-type device(smart watch) which patients wear and server system are developed in this paper. Smart watch developed includes GPS, accelerometer and illumination sensor, and can obtain real time health information by measuring the position of patients, quantity of exercise and amount of sunlight. Server system includes the sensor data analysis algorithm and web server that doctor and protector can monitor through sensor data acquired from smart watch. The proposed data analysis algorithm acquires quantity of exercise information and detects step count in patients' motion acquired from acceleration sensor and to verify this, the three cases with fast pace, slow pace, and walking pace show 96% of the experimental result. If developed u-Healthcare System for dementia patients is applied, more high-quality medical service can be provided to patients.

• Korean Journal of Biological Psychiatry
• /
• v.23 no.2
• /
• pp.63-68
• /
• 2016

Objectives Haenyeo are Korean professional women breath-hold divers in Jeju island. The aim of this study was to investigate the clinical characteristics of depressed Haenyeo group, compared to non-Haenyeo depressed group. Methods This study included 75 Haenyeo and 340 non-Haenyeo with depressive disorders recruited from the Dementia Early Detection Program in Jeju island. Structural diagnostic interviews were performed using the Korean version of Mini International Neuropsychiatric Interview. All patients completed the questionnaires, including the Subjective Memory Complaints Questionnaire (SMCQ), the Patient Health Questionnaire-15 (PHQ-15), and the Blessed dementia scale. Depression was evaluated by the Korean version of short form the Geriatric Depression Scale (K-SGDS) and cognition was assessed by the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) assessment packet. Results Although the mean scores of the K-SGDS were similar between Haenyeo and non-Haenyeo depressed groups, the Haenyeo group showed a higher mean score on the PSQ-15 (p < 0.001, ANCOVA adjusting for age, the K-SGDS and education). The Haenyeo group showed poorer performance on the Korean Version of Frontal Assessment Batter (p < 0.001), the Mini-Mental State Examination in the Korean version of the CERAD Assessment Packet (p < 0.018), the word fluency test (p < 0.001), and the word list memory test (p = 0.012) in ANCOVA adjusting for age and education. The mean SMCQ score was higher in the Haenyeo depressed group than in the non-Haenyeo depressed group. Conclusions The Haenyeo depressed group shows cognitive dysfunction, especially frontal lobe dysfunction, compared to the non-Haenyeo depressed group, indicating the Haenyeo depressed group may have more severe frontolimbic dysfunction due to chronic exposure to hypoxia. The Haenyeo depressed group suffers more somatic symptoms than the non-Haenyeo depressed group.

• Korean Journal of Psychosomatic Medicine
• /
• v.24 no.2
• /
• pp.200-207
• /
• 2016

Objectives : Alzheimer's disease(AD) is characterized by progressive decline of cognitive function and also by various behavioral psychological symptoms of dementia(BPSD) which causes distress to their caregivers. The purpose of this study was to investigate association between each AD patients' behavioral psychological symptoms and their caregivers' burden. Methods : Participants were 80 AD patients and their caregivers. We used Korean neuropsychiatric inventory (K-NPI) to assess the symptoms of patients and Korean version of Zarit Burden Interview(ZBI) to evaluate caregivers' burden. Results : The results showed ZBI score, which is the index for caregivers' burden, had a statistically significant positive correlation with the frequency of delusion, hallucination, agitation/aggression, depression, anxiety, disinhibition and irritability, the severity of hallucination, agitation/aggression, anxiety, disinhibition, aberrant motor, and sleep, and the global score(frequency${\times}$severity) for delusion, hallucination, agitation/aggression, depression, anxiety, disinhibition, aberrant motor, and sleep. There were significant correlations between each scale for cognitive function(i.e. MMSE-KC, CDR, GDS) and ZBI scale. Correlations between each scale for activity of daily living(i.e. Barthel -ADL, K-ADL) and ZBI scale were also significant. Conclusions : There were a significant correlation between BPSD and caregiver burden. Caregiver burden was also correlated with cognitive function and activity of daily living. Early detection and preventive treatment of these symptoms in BPSD might make improvement of caregivers' quality of life as well as AD patients'.

• The Korean Journal of Physiology and Pharmacology
• /
• v.18 no.6
• /
• pp.447-456
• /
• 2014

Until now, a disease-modifying therapy (DMT) that has an ability to slow or arrest Alzheimer's disease (AD) progression has not been developed, and all clinical trials involving AD patients enrolled by clinical assessment alone also have not been successful. Given the growing consensus that the DMT is likely to require treatment initiation well before full-blown dementia emerges, the early detection of AD will provide opportunities to successfully identify new drugs that slow the course of AD pathology. Recent advances in early detection of AD and prediction of progression of the disease using various biomarkers, including cerebrospinal fluid (CSF) $A{\beta}_{1-42}$, total tau and p-tau181 levels, and imagining biomarkers, are now being actively integrated into the designs of AD clinical trials. In terms of therapeutic mechanisms, monitoring these markers may be helpful for go/no-go decision making as well as surrogate markers for disease severity or progression. Furthermore, CSF biomarkers can be used as a tool to enrich patients for clinical trials with prospect of increasing statistical power and reducing costs in drug development. However, the standardization of technical aspects of analysis of these biomarkers is an essential prerequisite to the clinical uses. To accomplish this, global efforts are underway to standardize CSF biomarker measurements and a quality control program supported by the Alzheimer's Association. The current review summarizes therapeutic targets of developing drugs in AD pathophysiology, and provides the most recent advances in the clinical utility of CSF biomarkers and the integration of CSF biomarkers in current clinical trials.